VXRT Stock Price
For anyone interested in the latest updates and insights related to VXRT stock price and news, FintechZoom provides a comprehensive platform that offers real-time information and analysis.
Stock Overview
This “Stock Overview” table offers a snapshot of a company’s performance.
Price: This is the current market value, telling you how much one share costs.
Change: This shows how much the price moved compared to yesterday, green for up, red for down.
Volume: This tells you how many shares were traded, suggesting activity and investor interest.
High/Low/Open: These show the price range during the day and where it started (open) and finished (close).
Previous Close: This is yesterday’s closing price, providing context for today’s change.
52-Week High/Low: These tell you the stock’s peak and valley over the past year, helping assess current price relative to its broader trend.
VXRT Stock News
VXRT Stock Prices Change
History of Vaxart Inc.
Vaxart, Inc. is a clinical-stage biotechnology company focused on the development of orally administered recombinant vaccines using a proprietary delivery platform known as VAAST (Vector-Adjuvant-Antigen Standardized Technology). Vaxart’s vaccines are designed to be administered using convenient, room temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. This approach aims to address several challenges associated with traditional needle-based vaccines, including needle-phobia, vaccine hesitancy, and the need for cold chain distribution.
Early Years and Development of VAAST
The company was founded in 2004 by Sean Tucker, a seasoned entrepreneur with extensive experience in the biotechnology industry. Tucker envisioned a more convenient and accessible method of vaccination and recognized the potential of oral delivery technology to address these challenges. Vaxart’s proprietary VAAST platform utilizes a combination of adenovirus vectors, TLR3 agonists, and a stabilizing technology to deliver vaccine antigens directly to the mucosal immune system, which plays a crucial role in protecting the body from pathogens that enter through the mouth, nose, and gut.
Pipeline of Vaccine Candidates
Vaxart’s development pipeline currently includes several promising vaccine candidates targeting a wide range of infectious diseases. Their most advanced programs include:
COVID-19 Vaccine: Vaxart is developing an oral tablet vaccine for COVID-19, which has demonstrated strong immune responses in preclinical studies. Their approach targets the spike protein of the SARS-CoV-2 virus, the primary target of traditional COVID-19 vaccines.
Norovirus Vaccine: Norovirus is a highly contagious gastrointestinal virus that causes severe diarrhea, vomiting, and abdominal cramps. Vaxart is developing an oral tablet vaccine for norovirus, which aims to provide protection against both the Norwalk and GII rotavirus strains.
Seasonal Influenza Vaccine: Vaxart is developing an oral tablet vaccine for seasonal influenza, which would address the need for annual vaccination and potentially reduce vaccine hesitancy associated with needle injections.
Respiratory Syncytial Virus (RSV) Vaccine: RSV is a major cause of respiratory infections in infants and young children. Vaxart is developing an oral tablet vaccine for RSV, which could help reduce RSV-related hospitalizations and improve respiratory health in children.
Human Papillomavirus (HPV) Therapeutic Vaccine: Vaxart is developing a therapeutic oral tablet vaccine for HPV, which could treat existing HPV infections and prevent progression to cervical cancer. This would be a novel approach to HPV management, potentially improving treatment outcomes and reducing the burden of cervical cancer.
Recent Milestones and Ongoing Trials
Vaxart has made significant progress in recent years, advancing several vaccine candidates into clinical trials. In 2020, the company initiated Phase I trials for their COVID-19 vaccine and Phase II trials for their norovirus vaccine. In 2022, they initiated Phase II trials for their seasonal influenza vaccine. Vaxart’s HPV therapeutic vaccine is also expected to enter clinical trials in the near future.
The company has raised substantial funding throughout its development, demonstrating investor confidence in its innovative approach to vaccine delivery. Vaxart’s unique technology and promising pipeline of vaccine candidates have the potential to revolutionize the way vaccines are administered, offering a more convenient, accessible, and effective way to protect against infectious diseases.
Officers and Directors
Buy VXRT Stock
FintechZoom News
VXRT Stock Price History
VXRT Stock Reddit
[wp-rss-aggregator feeds=”VXRT”]